| scholarly article | Q13442814 |
| P2093 | author name string | Choli Hartono | |
| Surya V Seshan | |||
| Thangamani Muthukumar | |||
| Manikkam Suthanthiran | |||
| Marie Matignon | |||
| P2860 | cites work | A new equation to estimate glomerular filtration rate | Q24651973 |
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation | Q34124202 | ||
| Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. | Q39716270 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 | ||
| Summary of FDA antibody-mediated rejection workshop | Q42598786 | ||
| Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 | ||
| Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection | Q43193957 | ||
| Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. | Q43236422 | ||
| Effect of histological damage on long-term kidney transplant outcome | Q43547328 | ||
| Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 | ||
| A personal perspective: 100-year history of the humoral theory of transplantation | Q48462214 | ||
| Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 | ||
| Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. | Q53244973 | ||
| The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). | Q64964742 | ||
| Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection | Q67773387 | ||
| Role of humoral presenitization in human renal transplant rejection | Q72145369 | ||
| Capillary deposition of C4d complement fragment and early renal graft loss | Q72791721 | ||
| Early versus late acute rejection episodes in renal transplantation | Q78841495 | ||
| Determinants of poor graft outcome in patients with antibody-mediated acute rejection | Q80054529 | ||
| Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 | ||
| Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes | Q83610924 | ||
| De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure | Q84752864 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risk factor | Q1475848 |
| P304 | page(s) | 603-611 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection | |
| P478 | volume | 94 |
| Q39826008 | Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay |
| Q40108113 | Acute Cellular Rejection and C4d Positivity in Heart Transplantation : A Manifestation of Asymptomatic Antibody-Mediated Rejection? |
| Q26996813 | Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q47286616 | Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. |
| Q89707602 | High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury |
| Q38967641 | Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study |
| Q47786299 | Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study. |
| Q42682772 | Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients. |
| Q86047153 | Positive C4d in kidney transplantation biopsy: clinical impact |
| Q38258153 | The increasing clinical importance of alloantibodies in kidney transplantation |
| Q42102593 | Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center. |
| Q50743724 | Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection. |
Search more.